https://doi.org/10.4081/reumatismo.2019.1102
Novel autoantibodies in rheumatoid arthritis
Accepted: 6 September 2018
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Rheumatoid factor and antibodies against cyclic citrullinated peptides represent a diagnostic hallmark in rheumatoid arthritis (RA). However, over the last decades many other autoantibodies have been identified. Several proteins can trigger an aberrant autoimmune response in their native form while others acquire this feature after post-translational modifications such as citrullination, carbamylation or acetylation. It is of interest that also the enzymes catalyzing such post-translational modifications (e.g. the protein arginine deiminases) can transform themselves into autoantibodies in RA. The purpose of this review article is to provide an overview of relevant literature published over the last years regarding novel autoantibodies and their possible diagnostic and prognostic significance in RA.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- G. Fornaciari, V. Giuffra, Rheumatic diseases at the court of the Medici of Florence: the so-called “gout” of the Medici , Reumatismo: Vol. 61 No. 3 (2009)
- Virginia Annese, Paola Tomietto, Paolo Venturini, Serena D'Agostini, Gianfranco Ferraccioli, Migraine in SLE: role of antiphospholipid antibodies and Raynaud’s phenomenon , Reumatismo: Vol. 58 No. 1 (2006)
- B. Seriolo, S. Paolino, A. Sulli, M. Cutolo, Are there any positive effects of TNF-alpha blockers on bone metabolism? , Reumatismo: Vol. 58 No. 3 (2006)
- G. Valesini, M. Cutolo, Effects of TNF antagonists on immune and neuroendocrine system , Reumatismo: Vol. 57 No. s4 (2005)
- P. Quattrocchi, A. Barrile, D. Bonanno, L. Giannetto, M. Patafi, V. Tigano, B. Ferlazzo, The role of anti-nucleosome antibodies in systemic lupus erythematosus. Results of a study of patients with systemic lupus erythematosus and other connective tissue diseases , Reumatismo: Vol. 57 No. 2 (2005)
- G. La Montagna, G. Cuomo, I. Chiarolanza, L. Ruocco, G. Valentini, HAQ-DI Italian version in systemic sclerosis , Reumatismo: Vol. 58 No. 2 (2006)
- F.M. Perrotta, S. Scriffignano, A. De Socio, E. Lubrano, Occult axial involvement in patients with psoriatic arthritis mutilans: a case report , Reumatismo: Vol. 71 No. 2 (2019)
- M. Ricci, G. De Marco, F. Desiati, D. Mazzocchi, L. Rotunno, N. Battafarano, A. Marchesoni, Long-term survival of methotrexate in psoriatic arthritis , Reumatismo: Vol. 61 No. 2 (2009)
- G.D. Sebastiani, Antineutrophil cytoplasmic antibodies , Reumatismo: Vol. 61 No. 1 (2009)
- R. Assari, P. Sadeghi, A. Mirmohammadsadeghi, F. Ebadi, V. Ziaee, Macrophage activation syndrome as a complication of rheumatologic disorders, a report from Iran , Reumatismo: Vol. 71 No. 4 (2019)
<< < 24 25 26 27 28 29 30 31 32 33 > >>
You may also start an advanced similarity search for this article.
